The Monarch external Trigeminal Nerve Stimulation (eTNS) System, which is the size of a cell phone, emits a low-level electrical pulse through a wire to a small patch attached to a patient’s forehead, stimulating branches of the trigeminal nerve and sending therapeutic signals to parts of the brain believed to be associated with ADHD.
In a clinical trial comparing eTNS to a placebo device, subjects who used eTNS every night for four weeks experienced statistically significant improvement in their ADHD symptoms, according to the FDA.
The prescription-only eTNS system, the first non-drug ADHD treatment approved by the FDA, can be used by children between the ages of 7 and 12 who are not currently on medication for ADHD. The device is designed for home use, to be employed and monitored by a caregiver while the patient sleeps.
The FDA’s approval allows NeuroSigma, a Los Angeles-based biotech company focused on developing therapies involving Trigeminal Nerve Stimulation (TNS) technology, to market the device in the U.S.
More articles about health IT:
Viewpoint: With restructuring and retraining, AI will enhance — not steal — jobs
Amazon’s Alexa to offer voice skill for therapy
HHS continues to deploy strong cybersecurity solutions, report finds
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
